Vermillion Pharmaceuticals Inc. (VRML)

Oncology Corporate Profile

Stock Performance

1.3500
-0.0200

HQ Location

12117 Bee Caves Rd Building III, Suite 100
Austin, TX 78738

Company Description

Vermillion is focused on the discovery, development, and commercialization of novel, high-value diagnostic tests that provide physicians with information to better manage and improve patient care. Vermillion is developing diagnostic products in a variety of clinical areas including cardiology, oncology and hematology.

Website: http://www.vermillion.com/

Brand Generic Indication
OVA1«•diagnosticOvarian cancer

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Ovarian Tumor Triage TestdiagnosticsOvarian cancer BiomarkerDevelopment
Ovarian Cancer Prognosis TestdiagnosticsOvarian cancer BiomarkerDevelopment
Ovarian Cancer High-Risk Triage TestdiagnosticsOvarian cancer BiomarkerDevelopment

View additional information on product candidates here »

Source


http://www.vermillion.com/

Recent News Headlines

Vermillion Receives FDA 510(k) Clearance for Overa

3/21/2016 11:52 am

(GenomeWeb) Mar 21, 2016 – Vermillion today said it has received US Food and Drug Administration 510(k) clearance for its Overa ovarian cancer test.

AmerisourceBergen Makes 2nd Multibillion-Dollar Purchase This Year

10/6/2015 01:00 pm

(Philadelphia Business Journal/Morning Edition) Oct 6, 2015 - AmerisourceBergen signed a definitive agreement Tuesday to buy Pharmedium Healthcare Holdings Inc. for $2.6 billion.

Alkermes' Schizophrenia Drug Aristada Gets FDA Nod

10/6/2015 12:05 pm

(Reuters) Oct 5, 2015 - The U.S. Food and Drug Administration on Monday approved Alkermes Plc's longer-acting injectable version of blockbuster schizophrenia pill Abilify, making the treatment available in two doses.

Precision Medicine Targets Pancreatic Cancer

10/6/2015 12:03 pm

(Medscape Medical News) Oct 6, 2015 - Next-generation sequencing can potentially provide valuable information for patients with pancreatic cancer.

FDA Expands Indication for Optune Device in Glioblastoma

10/6/2015 12:03 pm

(Medscape Medical News) Oct 6, 2015 - The US Food and Drug Administration (FDA) has expanded the indication for the Optune device (Novocare), which will allow it to be used to treat patients with newly diagnosed glioblastoma multiforme.

USPSTF Stays the Course on Colorectal Ca Screening

10/6/2015 12:03 pm

(MedPage Today) Oct 5, 2015 - Screening for colorectal cancer should begin at age 50 and continue through age 75, using fecal occult blood tests (FOBT), colonoscopy, or a combination of FOBT and endoscopy, according to updated draft recommendations from the U.S Preventive Services Task Force (USPSTF).

Drugmakers Say Pacific Trade Agreement to Stifle Investment

10/6/2015 12:02 pm

(Bloomberg) Oct 5, 2015 - The biotechnology industry criticized the deal struck by negotiators for the Trans-Pacific Partnership agreement, saying it would undermine innovation by offering only limited protection of the data that drugmakers keep secret from competitors.

For Prescription Drug Makers, Price Increases Drive Revenue

10/6/2015 12:01 pm

(Wall Street Journal) Oct 5, 2015 - Demand for a drug called Avonex has declined every year for the past 10. Not a problem for its manufacturer. U.S. revenue from the drug has more than doubled in that time, to $2 billion last year. The key: repeated price increases.

New Study Indicates Key Differences Between Trial Enrollees and Patients Receiving Treatments Necessitate Broader Eligibility Criteria and Monitoring of Real-World Practice Patterns

10/6/2015 11:00 am

(ASCO in Action) Oct 6, 2015 - A new article published in the Journal of Oncology Practice evaluates differences between treatment of patients with metastatic renal cell cancer (mRCC) who participated on clinical trials versus those who received the same therapy in routine clinical practice.

Roche Says Data Shows Cotellic Combination Therapy Effective

10/6/2015 10:03 am

(Reuters) Oct 6, 2015 - Swiss drugmaker Roche said final survival data from a Phase III clinical trial showed the Cotellic drug used in combination with Zelboraf helped people with previously untreated BRAF V600 mutation-positive advanced melanoma live significantly longer compared to Zelboraf alone.

CEM15: Surgical Limits In Metastatic Kidney Cancer

10/6/2015 10:02 am

(European Association of Urology) Oct 4, 2015 - Not all patients with advanced kidney cancer would benefit from nephrectomy, prompting experts to consider other less radical or aggressive options such as partial nephrectomy or lymph node dissection.

Dana-Farber Asserts Joint Inventorship On Cancer Immunotherapy Patents

10/6/2015 10:02 am

(Dana-Farber) Oct 1, 2015 - Dana-Farber is petitioning a federal court to determine that one of its scientists, Gordon Freeman, PhD, and another researcher are co-inventors on a series of cancer immunotherapy patents previously issued to a Japanese researcher and Japanese drug company.

BIDMC Cancer Center and JAX Launch Pilot Grant Program

10/6/2015 10:02 am

(BIDMC) Oct 2, 2015 - To advance cancer research and accelerate personalized genomic medicine, the Cancer Center at Beth Israel Deaconess Medical Center (BIDMC) and The Jackson Laboratory (JAX) have launched seven joint research projects to study a variety of cancer types, including multiple myeloma, lung, breast, prostate and brain cancers.

Rt. 34 Accident Claims Life Of Cancer Society Director

10/6/2015 10:02 am

(Asbury Park Press [NJ]) Oct 5, 2015 - A freak accident took the life of a borough resident and head of New Jersey's chapter of the Leukemia and Lymphoma Society on Saturday.

FDA Orders Manufacturers To Study Cleaning Problems With Medical Scopes Linked To Infections

10/6/2015 10:02 am

(Washington Post/To Your Health) Oct 5, 2015 - The Food and Drug Administration, hoping to prevent future outbreaks of deadly bacterial infections at U.S. hospitals, on Monday ordered makers of specialized medical scopes to undertake new studies of how the devices are cleaned.

bioTheranostics Announces Collaboration with DeNovo Sciences to Evaluate Its Proprietary Cancer Biomarkers for Use in Liquid Biopsies

10/6/2015 10:01 am

(Yahoo! Finance) Oct 6, 2015 - bioTheranostics, Inc., a leader in molecular diagnostics for cancer, today announced a collaboration agreement with DeNovo Sciences, Inc., an innovator in the emerging liquid biopsy field, to investigate the technical feasibility of utilizing bioTheranostics’ proprietary biomarkers in the development of blood-based diagnostics.

Phase III Study Confirms Benefits of Lenalidomide Maintenance Therapy for Patients with Multiple Myeloma

6/1/2015 06:01 pm

(RPCI) May 31, 2015 - A large cooperative-group study directed by the Alliance for Clinical Trials in Oncology has confirmed previous evidence that the drug lenalidomide delays time to disease progression for patients with multiple myeloma and is an important treatment option for patients with this rare but increasingly common cancer of the blood and marrow.

Vermillion Approved for a $7.5 Million Grant by the Cancer Prevention and Research Institute of Texas

5/21/2015 12:45 pm

(Benzinga) May 21, 2015 - Vermillion, Inc. announced today that it has been approved for a product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT) for $7.5 million, to help fund the Company's new multi-site pelvic mass registry.

Kaiser Permanente Southern California and Vermillion Collaborate to Improve Best-Practice Care for Women with Ovarian Cancer

4/14/2015 12:20 pm

(Benzinga) Apr 14, 2015 - Vermillion, Inc. today announced the initiation of a strategic partnership with Kaiser Permanente's Southern California Permanente Medical Group in order to enhance the diagnosis and treatment of ovarian cancer.

Robotic Prostate Cancer Surgery Offers Patients Better, More Effective Results

5/6/2014 07:01 am

(StreetInsider) May 6, 2014 - A recent study from UCLA has found that robotic-assisted prostatectomy offers a number of advantages over traditional prostatectomy procedures. These benefits include a lower likelihood of patients needing additional treatment and fewer side effects than other prostate cancer treatments.

Vermillion Launches ASPiRA LABS

4/28/2014 12:19 pm

(MarketWatch) Apr 28, 2014 - Vermillion today launched ASPiRA LABS, which will specialize in applying the latest biomarker-based technologies to address critical needs in the management of gynecologic cancers.

Vermillion Launches ASPiRA LABS

4/28/2014 12:01 pm

(MarketWatch) Apr 28, 2014 - Vermillion today launched ASPiRA LABS, which will specialize in applying the latest biomarker-based technologies to address critical needs in the management of gynecologic cancers.

Novel Assay Developed for Detecting ALK Rearrangement in NSCLC

2/24/2014 11:05 am

(IASLC) Feb 24, 2014 - Researchers have developed a novel technique for detecting ALK rearrangements in non-small cell lung cancers (NSCLCs) that is more sensitive and easier to perform than currently available techniques.

CancerCare Joins WellPoint Foundation to Improve the Health of Caregivers

2/13/2013 12:03 pm

(Yahoo! Finance) Feb 13, 2013 - Help for Cancer Caregivers web tool provides personalized resources and support.

Vermillion Sees Positive Results From Ovarian Cancer Test Study; Shares Soar

11/28/2012 12:08 pm

(Wall Street Journal) Nov 28, 2012 - Vermillion Inc. said results from a study of its ovarian cancer test were positive.

Vermillion Sees Positive Results From Ovarian Cancer Test Study; Shares Soar

11/28/2012 12:00 pm

(Wall Street Journal) Nov 28, 2012 - Vermillion Inc. said results from a study of its ovarian cancer test were positive.

Vermillion Ovarian Cancer Test Shows Positive Result

7/30/2012 10:24 am

(Reuters) July 30, 2012 - Diagnostics company Vermillion Inc. said a clinical trial of its blood test for detecting ovarian cancer showed the test had a high chance of correctly identifying patients with cancer.

Vermillion Ovarian Cancer Test Shows Positive Result

7/30/2012 10:02 am

(Reuters) July 30, 2012 - Diagnostics company Vermillion Inc. said a clinical trial of its blood test for detecting ovarian cancer showed the test had a high chance of correctly identifying patients with cancer.

Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions

6/15/2012 03:03 pm

[PR Newswire] - AUSTIN, Texas, June 15, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, reported that results of the recent Peripheral Artery Disease (PAD) multi-marker intended ...